CORT Aug 2024 45.000 put
- GlobeNewswire
Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome)
MENLO PARK, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the results from GRACE, the Phase 3 trial of its proprietary selective cortisol modulator relacorilant in patients with hypercortisolism (Cushing’s syndrome), will
- Zacks
Corcept (CORT) Up 24.5% Since Last Earnings Report: Can It Continue?
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GuruFocus.com
Insider Sale: Chief Development Officer William Guyer Sells 30,000 Shares of Corcept ...
On May 28, 2024, William Guyer, the Chief Development Officer of Corcept Therapeutics Inc (NASDAQ:CORT), executed a sale of 30,000 shares of the company.
